ArticleFrontiers in oncology2025
Long-term survival after solitary ocular metastasis following radical resection of esophagogastric junction carcinoma: a rare case report.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Isolated ocular metastasis from esophagogastric junction (EGJ) cancer is extremely rare, and no standardized therapeutic approach has been established to date. Reporting such cases may help clarify optimal management strategies for uncommon metastatic patterns. Case presentation: We describe a 44-year-old male patient who developed isolated ocular oligometastasis 10 months after radical EGJ cancer resection. Comprehensive evaluation confirmed left eye involvement. Following multidisciplinary team (MDT) discussion, a combined treatment plan was implemented, starting with systemic therapy consisting of docetaxel, tegafur/gimeracil/oteracil (S-1), and tislelizumab. After achieving disease stabilization, the patient underwent left eye enucleation with ocular prosthesis implantation, followed by adjuvant radiotherapy and maintenance S-1 chemotherapy. At a 55-month follow-up, he remains disease-free with an excellent performance status (PS 0). Conclusion: This case highlights that integrated multimodal therapy-including systemic and local interventions-can result in long-term survival for patients with isolated ocular metastasis from EGJ cancer. MDT-based, individualized treatment planning is essential for optimizing outcomes in rare metastatic scenarios and may inform future precision oncology approaches.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.